References
- Battisti, W. P., Wager, E., Baltzer, L., Bridges, D., Cairns, A., Carswell, C. I., Citrome, L., Gurr, J. A., Mooney, L. A., Moore, B. J., Peña, T., Sanes-Miller, C. H., Veitch, K., Woolley, K. L., & Yarker, Y. E. (2015). Good publication practice for communicating company-sponsored medical research: GPP3. Annals of Internal Medicine, 163(6), 461–464. https://doi.org/https://doi.org/10.7326/M15-0288
- Jureidini, J. N., Amsterdam, J. D., & McHenry, L. B. (2016). The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance. The International Journal of Risk & Safety in Medicine, 28(1), 33–43. https://doi.org/https://doi.org/10.3233/JRS-160671
- Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics and Gynecology, 134(5), 899–908. https://doi.org/https://doi.org/10.1097/AOG.0000000000003500
- Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2021). Failure of a “meta-analysis”: A commentary on Glen Spielmans’ “Re-analyzing phase III bremelanotide trials for ‘hypoactive sexual desire disorder in women’”. Journal of Sex Research. https://doi.org/https://doi.org/10.1080/00224499.2021.1902926
- Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45. https://doi.org/https://doi.org/10.1371/journal.pmed.0050045
- Obstetrics & Gynecology. (2020). Instructions for authors: Obstetrics & gynecology. Lippincott Williams & Wilkins. https://journals.lww.com/greenjournal/Pages/instructionsforauthors.aspx
- Revicki, D. A., Clayton, A. H., Stouch, B. C., Portman, D. J., Kingsberg, S. A., DeRogatis, L. R., & Jordan, R. (2018, February 20). Developing clinically meaningful responder thresholds for primary endpoints for clinical trials in premenopausal women with hypoactive sexual desire disorder. International Society for CNS Trials and Methodology.
- Schulz, K. F., Altman, D. G., Moher, D., & Group, C. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Medicine, 7(3), e1000251. https://doi.org/https://doi.org/10.1371/journal.pmed.1000251
- Spielmans, G. I. (2021). Re-analyzing phase III bremelanotide trials for “hypoactive sexual desire disorder” in women. Journal of Sex Research. https://doi.org/https://doi.org/10.1080/00224499.2021.1885601
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252–260. https://doi.org/https://doi.org/10.1056/NEJMsa065779
- United States Food and Drug Administration. (2019). New drug application multi-disciplinary review and evaluation standard 210557: Vyleesi/Bremelanotide. United States Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000TOC.cfm
- Zucker, K. J. (2021). Archives at 50 years. Archives of Sexual Behavior, 50(1), 1–6. https://doi.org/https://doi.org/10.1007/s10508-021-01913-0